Table 3.
Afatinib treatment line | ||
---|---|---|
Any (N = 49) | First (n = 36) | |
Response, n (%) | ||
Overall | 37 (75.5) | 28 (77.8) |
Complete | 11 (22.4) | 7 (19.4) |
Partial | 26 (53.1) | 21 (58.3) |
Stable disease | 3 (6.1) | 2 (5.6) |
Progressive disease | 6 (12.2) | 4 (11.1) |
Not evaluable | 3 (6.1) | 2 (5.6) |